These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 14508882

  • 1. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T, Anaissie E.
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [Abstract] [Full Text] [Related]

  • 2. Invasive fungal infections in liver transplantation.
    Liu X, Ling Z, Li L, Ruan B.
    Int J Infect Dis; 2011 May; 15(5):e298-304. PubMed ID: 21345708
    [Abstract] [Full Text] [Related]

  • 3. The place for itraconazole in treatment.
    Maertens J, Boogaerts M.
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
    [Abstract] [Full Text] [Related]

  • 4. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR.
    Clin Infect Dis; 2007 Feb 01; 44(3):402-9. PubMed ID: 17205448
    [Abstract] [Full Text] [Related]

  • 5. Recent advances and challenges in the treatment of invasive fungal infections.
    Shao PL, Huang LM, Hsueh PR.
    Int J Antimicrob Agents; 2007 Dec 01; 30(6):487-95. PubMed ID: 17961990
    [Abstract] [Full Text] [Related]

  • 6. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR, Slavin MA, Donnelly JP.
    Br J Haematol; 2011 Jun 01; 153(6):681-97. PubMed ID: 21504422
    [Abstract] [Full Text] [Related]

  • 7. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J.
    Eur J Haematol; 2007 Apr 01; 78(4):275-82. PubMed ID: 17241370
    [Abstract] [Full Text] [Related]

  • 8. Antifungal treatment strategies in high risk patients.
    Rüping MJ, Vehreschild JJ, Cornely OA.
    Mycoses; 2008 Sep 01; 51 Suppl 2():46-51. PubMed ID: 18721331
    [Abstract] [Full Text] [Related]

  • 9. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC, Dockrell DH.
    J Infect; 2007 Oct 01; 55(4):287-99. PubMed ID: 17697716
    [Abstract] [Full Text] [Related]

  • 10. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
    Murali S, Langston A.
    Transpl Infect Dis; 2009 Dec 01; 11(6):480-90. PubMed ID: 19725908
    [Abstract] [Full Text] [Related]

  • 11. Early diagnosis of fungal infection in immunocompromised patients.
    Barnes RA.
    J Antimicrob Chemother; 2008 Jan 01; 61 Suppl 1():i3-6. PubMed ID: 18063601
    [Abstract] [Full Text] [Related]

  • 12. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
    Salavert M.
    Int J Antimicrob Agents; 2008 Nov 01; 32 Suppl 2():S149-53. PubMed ID: 19013340
    [Abstract] [Full Text] [Related]

  • 13. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G, Kontoyiannis DP.
    Curr Opin Infect Dis; 2006 Aug 01; 19(4):380-5. PubMed ID: 16804387
    [Abstract] [Full Text] [Related]

  • 14. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M, Kim J, Marty FM, Schwarzinger M, Koo S.
    PLoS One; 2015 Aug 01; 10(11):e0140930. PubMed ID: 26554923
    [Abstract] [Full Text] [Related]

  • 15. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
    Leather HL, Wingard JR.
    Blood Rev; 2006 Sep 01; 20(5):267-87. PubMed ID: 16781028
    [Abstract] [Full Text] [Related]

  • 16. [Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
    Doubek M, Mayer J, Horký D, Doubek J, Rácil Z, Vorlícek J.
    Vnitr Lek; 2002 Mar 01; 48(3):248-54. PubMed ID: 11968587
    [Abstract] [Full Text] [Related]

  • 17. [Up-date on the treatment of serious fungal infections].
    Borges Sa M.
    Rev Esp Quimioter; 2008 Mar 01; 21 Spec No 1():14-25. PubMed ID: 18752076
    [Abstract] [Full Text] [Related]

  • 18. Antifungal prophylaxis for invasive mycoses in high risk patients.
    Ullmann AJ, Cornely OA.
    Curr Opin Infect Dis; 2006 Dec 01; 19(6):571-6. PubMed ID: 17075333
    [Abstract] [Full Text] [Related]

  • 19. Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts.
    Hathorn JW.
    Hematol Oncol Clin North Am; 1993 Oct 01; 7(5):1051-99. PubMed ID: 8226565
    [Abstract] [Full Text] [Related]

  • 20. Changing epidemiology of systemic fungal infections.
    Richardson M, Lass-Flörl C.
    Clin Microbiol Infect; 2008 May 01; 14 Suppl 4():5-24. PubMed ID: 18430126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.